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The development of strategies to induce anti-
bodies that potently inhibit HIV-1 infection is 
the highest priority for HIV-1 vaccine develop-
ment (Mascola et al., 2005a). Rare human mAbs 
(2F5, 4E10, and Z13 against the membrane-
proximal region of gp41 [Muster et al., 1993; 
Stiegler et al., 2001; Zwick et al., 2001], IgG1b12 
against the CD4 binding site of gp120 [Roben 
et al., 1994], and mAb 2G12 against gp120 high 
mannose residues [Sanders et al., 2002]) have 
been developed that can broadly neutralize 
HIV-1 in vitro. Passive infusion of 2F5 and 
2G12, along with hyperimmune HIV immuno-
globulin (HIVIG), has protected nonhuman   
primates from SIV-HIV chimeric virus (SHIV) 
infections in vivo (Baba et al., 2000; Mascola   
et al., 2000). To date, no immunogen has in-
duced neutralizing antibodies that mimic these 
rare  broadly  neutralizing  antibodies.  Despite 
intense investigation, it remains unclear why, 
in both animal models and humans, these kinds 
of broadly neutralizing antibodies are not rou-
tinely  induced  (Binley  et  al.,  2008;  Li  et  al., 
2009; Sather et al., 2009; Shen et al., 2009). Sev-
eral hypotheses have been advanced, including   
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Traditional antibody-mediated neutralization of HIV-1 infection is thought to result from 
the binding of antibodies to virions, thus preventing virus entry. However, antibodies that 
broadly neutralize HIV-1 are rare and are not induced by current vaccines. We report that 
four human anti-phospholipid monoclonal antibodies (mAbs) (PGN632, P1, IS4, and CL1) 
inhibit HIV-1 CCR5-tropic (R5) primary isolate infection of peripheral blood mononuclear 
cells (PBMCs) with 80% inhibitory concentrations of <0.02 to 10 µg/ml. Anti-phospholipid 
mAbs inhibited PBMC HIV-1 infection in vitro by mechanisms involving binding to monocytes 
and triggering the release of MIP-1 and MIP-1. The release of these -chemokines explains 
both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures contain-
ing both primary lymphocytes and monocytes.
© 2010 Moody et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e764 Anti-phospholipid antibody inhibition of HIV-1 | Moody et al.
human anti-phospholipid mAbs can inhibit HIV-1 infection, 
and we demonstrate that the mechanism of inhibition is stim-
ulation of an innate anti–HIV-1 response, including the release 
of soluble chemokines which block HIV-1 entry.
RESULTS
Analysis of anti-phospholipid antibody inhibition of HIV-1 
infectivity in epithelial cell–based pseudovirus infection  
and PBMC infection inhibition assays
First, the ability of anti-phospholipid mAbs (Table I) to   
inhibit  R5  HIV-1  envelope  (Env)  pseudoviruses  B.PVO, 
B.6535, and C.DU123 in the TZM-bl epithelial cell pseudo-
virus infectivity assay was determined (Montefiori, 2005). 
None of these anti-phospholipid mAbs could inhibit pseudo-
virus infectivity, whereas broadly neutralizing mAb 4E10   
potently neutralized all three viruses in this assay (Table S1). 
Similarly, none of these anti-phospholipid mAbs inhibited 
fusion-competent CXCR4-tropic (X4) B.MN or CCR5-
tropic (R5) B.ADA and B. AD8 HIV-1 mediated fusion in 
Sup-T1 T cells, whereas the broadly neutralizing mAbs 2F5 
and 4E10 did inhibit syncytia formation (Table S2).
In contrast, four of the nine anti-phospholipid mAbs (IS4, 
CL1, P1, and PGN632) inhibited HIV-1 virion infectivity in 
PBMCs when tested against primary virus isolates correspond-
ing to the aforementioned Env pseudoviruses (Table II). A 
mixture of broadly neutralizing mAbs (IgG1b12, 2F5, and 
2G12, termed TriMab) was used as a positive control. Inter-
estingly, the mAbs in Table I that bound phospholipids in the 
presence and absence of 2GP1 (Fig. S1, A and B) were able 
to inhibit HIV-1 infectivity, whereas mAbs that did not bind 
phospholipids in the absence of 2GP1 had much more vari-
able inhibitory effects on HIV-1 infection, with only IS4 
showing consistent strong HIV-1 inhibitory activity (Table II). 
These data suggested that the mode of action of P1, PGN632, 
CL1, and IS4 might be mediated through binding to the lipids 
lack of immunogens that reflect the native trimer (Burton   
et al., 2005) and immunoregulatory constraints on production 
of rare species of broadly neutralizing antibodies (Haynes   
et al., 2005; Dunlop et al., 2008).
The methods used to test antibodies for their ability to 
inhibit HIV-1 infectivity can yield strikingly different results. 
Screening assays for anti–HIV-1 activity have used trans-
fected epithelial cell targets that express CD4 and CCR5, 
T cell lines which express CXCR4 and which can be used to 
measure virus induced syncytia, and assays using primary 
human PBMC and primary isolates of HIV-1 (Mascola et al., 
2005b). Panels of HIV-1 isolates that have differing sensitiv-
ity to inhibition in these assays have been suggested as a way 
to determine the potency of responses generated by vaccine 
candidates (Mascola et al., 2005b). Other assays, including 
assays  of  antibody-dependent  cell-mediated  cytotoxicity 
(Tyler et al., 1989) and antibody-dependent cell-mediated 
virus inhibition (ADCVI; Forthal et al., 2001), measure the 
ability of different components of the immune system to act 
in concert to inhibit HIV-1 infection by destroying infected 
targets and inhibiting virus replication. It is likely that any 
successful vaccine candidate will need to harness multiple arms 
of the immune system to be successful. This point has been 
emphasized by the failures of strategies aimed at inducing 
primarily B cell (Pitisuttithum et al., 2006) or T cell (Sekaly, 
2008) immunity, as well as the recent promising results from 
the RV144 trial (Dolgin, 2009).
One possible strategy to circumvent the problem of the 
induction of anti–HIV-1 antibodies is to search for antibodies 
with novel specificities that can inhibit HIV-1 infectivity   
and that could be potentially elicited by a vaccine strategy.   
Recently, Brown et al. (2007) have described a mouse mAb 
against  phosphatidylinositol  phosphate  that  neutralizes 
HIV-1 only in PBMC cultures and not in pseudovirus infection 
assays using epithelial cell targets. We now report that four 
Table I.  Anti-phospholipid monoclonal antibodies in this study
mAb Heavy chain Light chain Binds 
cardiolipin/PS
Binds HIV-1 
Env
Binds directly to 2GP1 Binding to CL/PS dependent 
on 2GP1
mAb origin
IS4 3 VH1  V2 ++  + Yes APS subject
CL1 3 VH1  V3 ++  ++ No SLE subject with APS
P1 1  ++  +++ No SLE subject with APS
PGN632 1  ++  + No uninfected and healthy 
subjecta
PGN401 1  +  + Yes humanized mouse mAb
B1 1  +  +++ Yes APS subject
B2 3  ++  + Yes APS subject
PGN635 1  +  + Yes uninfected and healthy 
subjecta
PGN634 1  +  + Yes uninfected and healthy 
subjecta
2F5 3  + + + No HIV-1 + subject
4E10 3  + + + No HIV-1 + subject
aDerived from an antibody library from normal subjects. PGN632 was further engineered to optimize binding to PS.JEM VOL. 207, April 12, 2010 
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founder viruses but not the dual-tropic R5/X4 B.WEAU3 
strain (Table IV). In addition, mAb PGN632 inhibited the 
infectivity of R5 SIVmac251 in rhesus PBMC (unpublished 
data). Thus, anti-phospholipid antibodies could inhibit the 
infectivity of R5 primary and transmitted/founded HIV-1 
isolates but could not inhibit the infectivity of any virus strains 
that used CXCR4 as a coreceptor.
Next the comparative potency and reproducibility of the 
anti-phospholipid mAb PGN632 was determined in inhibit-
ing HIV-1 B.BaL infectivity by assay of its anti–HIV-1 activity 
in PBMC from 75 different HIV-1–negative subjects (Fig. S2). 
HIV-1 infectivity was inhibited by mAb PGN632 in 85% of 
the PBMCs with a mean 80% inhibitory concentration (IC80) 
of 0.6 µg/ml and a range of 0.01–24 µg/ml for this 85% of 
positives. Thus, wide variation was seen in the potency of mAb 
PGN632 in different donor PBMC, where the mAb exhib-
ited exceptional potency in a majority of cases.
Time course of activity of anti-phospholipid antibodies
To study the kinetics of anti-phospholipid mAb inhibition of 
HIV-1 infection, mAbs were added at the time of addition of 
the virus or at 24, 48, and 72 h after adding virus to PBMC. 
of the virion, the target cell, or both in a specific orientation 
or packing.
Anti-phospholipid mAbs selectively inhibit infection  
of R5 HIV-1
Next, the breadth of neutralization of PGN632, P1, IS4, and 
CL1 mAbs was determined. Of eight R5 primary isolates 
tested, HIV-1 infectivity was inhibited by each of the four 
mAbs (Table III). When X4 viruses were tested, however, 
none of the four HIV-1 strains were inhibited. Recently, 
several env genes from transmitted/founder HIV-1 have been   
identified and isolated from plasmas of subjects soon after 
transmission (Keele et al., 2008). Thus, the ability of the   
anti-phospholipid mAbs to inhibit the infectivity of five   
such transmitted/founder Envs was tested using replication-
competent Renilla luciferase reporter HIV-1 encoding the 
respective env gene sequences. Four of the Envs were R5 
tropic and one (B.WEAU410) was dual R5/X4 tropic (Keele 
et al., 2008). Two reporter viruses expressing reference/
chronic Envs were included as controls (B.BaL [AY426110] 
and  B.SF162LS  [EU1123924]).  Anti-phospholipid  mAbs 
were able to inhibit the infectivity of four R5 transmitted/
Table II.  Assay for anti-phospholipid mAb inhibition of HIV-1 infectivity in a PBMC-based virus infection inhibition assay
Primary HIV-1 isolates mAbsa
IS4 CL1 P1 PGN632 PGN401 B1 B2 PGN635 PGN634 TriMabb
µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml
B.PVO 0.34 0.21 4.5 0.03 >50 >50 >50 >50 >50 0.64
B.6535 0.07 0.38 4.0 <0.02 >50 >50 >50 >50 >50 2.4
C.DU123 0.06 0.19 <0.02 <0.02 4.5 >50 >50 8.2 >50 >25
amAbs are shown as IC80 values (concentration of antibody resulting in 80% reduction of infection).
bTriMab = equal concentration mixture of IgG1b12, 2F5, and 2G12.
Table III.  Breadth of anti-phospholipid mAb inhibition of HIV-1 infectivity against 12 R5 and X4 HIV-1 and SHIV primary isolates 
in the PBMC infectivity assay
Primary HIV-1 isolates mAbsa Coreceptor usage
IS4 CL1 P1 PGN632 anti-RSV TriMabb
µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml
B.TORNO 0.58 0.73 17 0.09 >50 0.03 CCR5
B.PVO 0.34 0.21 4.5 0.03 >50 0.64 CCR5
B.6535 0.07 0.38 4.0 <0.02 >50 2.4 CCR5
C.DU123 0.06 0.19 <0.02 <0.02 >50 >25 CCR5
C.DU156 2.8 2.6 16 0.06 >50 >25 CCR5
C.DU151 3.1 1.1 1.2 <0.02 >50 >25 CCR5
C.DU172 1.1 0.62 0.55 <0.02 >50 >25 CCR5
SHIV 162P3 5.2 1.2 1.6 <0.02 >50 0.46 CCR5
SHIV 89.6P >50 >50 >50 >50 >50 1.5 CXCR4/CCR5
A.92UG029 >50 >50 >50 >50 >50 >50 CXCR4
B.MN >50 >50 >50 >50 >50 0.26 CXCR4
AE_01.NI1052 >50 >50 >50 >50 >50 >50 CXCR4
amAbs are shown as IC80 values.
bTriMab = equal concentration mixture of IgG1b12, 2F5, and 2G12.766 Anti-phospholipid antibody inhibition of HIV-1 | Moody et al.
lipid antibodies bound to HIV-1 Env (Table I). Similarly, SPR 
analysis was performed to determine anti-phospholipid mAb 
binding to intact Aldrithiol-2–inactivated B.ADA virions. P1, 
IS4, and CL1 mAbs did not bind to HIV-1 virions, whereas 
PGN632 mAb did bind, although with a fast off rate, likely 
explaining why this binding was not seen in the virus capture 
assay shown in Fig. S3 A (Fig. S3, B–D).
Two variations of the PBMC assay were next performed   
to further define the site of mAb inhibitory action in PBMC 
cultures. First, anti-phospholipid mAbs were preincubated 
with virus for 1 h before addition of the virus-antibody mixture 
to  PHA-activated  PBMC.  Second,  anti-phospholipid  mAbs 
were added first to PHA-activated PBMC for 1 h and then 
the PBMCs were washed before the virus being added. In both 
circumstances, the potency of anti-phospholipid mAb inhibition 
was equal (Fig. 1, A–D). Collectively with the finding that the 
anti-phospholipid mAbs did not bind stably to virions, these data 
indicated that the anti-phospholipid antibodies inhibited HIV-1 
infectivity by binding only to the PBMC and not to virions.
PBMC target of anti-phospholipid antibodies
To determine the cell type targeted by anti-phospholipid mAbs, 
different PBMC subsets were infected with HIV-1 Renilla 
luciferase reporter HIV-1 expressing B.BaL env and tested for 
inhibition with mAb PGN632 (Table VI). Although HIV-1 
NL-LucR.T2A-BaL.ecto infected CD4+ T cells, mAb PGN632 
Two of the mAbs were effective when added at later time 
points (Table V). For both antibodies, the inhibition was atten-
uated at the later time points. Significantly, both CL1 and 
PGN632 mAbs inhibited HIV-1 infectivity when added 48 h 
after the start of the infection with IC80s of 0.22 and 0.07 µg/ml, 
respectively. These data suggested that anti-phospholipid 
mAbs were inhibiting virus spread after one or more initial 
rounds of infection in PBMC cultures.
Site of action of anti-phospholipid antibodies
To determine the site of action of anti-phospholipid antibod-
ies, primary isolate B.BG1168 and B.SF162LS pseudovirions 
produced in PBMC and 293T cells, respectively, were incu-
bated in the presence or absence of soluble CD4 and then 
captured by immobilized anti-phospholipid, anti-HIV-1, and 
control mAbs. As expected, the anti-gp120 V3 loop mAb F39F 
was able to capture HIV-1 virions (Fig. S3 A). In addition, the 
anti-gp120 CCR5 binding site mAb 17b was able to capture 
virions in the presence but not in the absence of triggering   
by soluble CD4. In contrast, none of the anti-phospholipid 
mAbs were able to capture virions. To verify that the anti-
phospholipid antibodies were not reacting with HIV-1 Env, we   
performed surface plasmon resonance (SPR) analysis of anti-
phospholipid antibody reactivity with a series of recombinant 
Env oligomers. Although 2F5 and 4E10 mAbs bound well to 
JRFL and CON-S gp140 oligomers, none of the anti-phospho-
Table IV.  Breadth of anti-phospholipid mAb inhibition of HIV-1 infectivity against R5 and R5/X4 replicating HIV-1 Renilla reporter 
viruses engineered to express five transmitted/founder env genes, B.BaL env, and B.SF162LS env in the PBMC infectivity assay
HIV-1 genes in NL-LucR.
T2A-ENV.ecto virusesa
mAbsb Coreceptor usage
IS4 CL1 P1 PGN632 Anti-RSV 4E10
µg/ml µg/ml µg/ml µg/ml µg/ml µg/ml
B.BaL 0.58 2.2 0.11 <0.02 >50 1.6 CCR5
B.WITO 0.06 <0.02 <0.02 <0.02 >50 0.16 CCR5
B.CH040 <0.02 <0.02 <0.02 <0.02 >50 <0.02 CCR5
B.CH058 0.37 0.17 0.29 <0.02 >50 3.6 CCR5
B.CH077 16 46 5.5 0.07 >50 3.0 CCR5
B.SF162LS 1.5 2.6 0.4 <0.02 >50 2.5 CCR5
B.WEAU410 >50 >50 >50 >50 >50 4.5 CXCR4/CCR5
aTransmitted env genes were derived from patients WITO4160, 700-01-004-0, 700-01-005-8, 700-01-007-7, and WEAu0575, respectively.
bmAbs are shown as IC80 values.
Table V.  Effect of time of introduction on the inhibitory effect of anti-phospholipid mAbs against B.6535 in the PBMC assay
Time after infection mAbsa
IS4 CL1 P1 PGN632 Anti-RSV
h µg/ml µg/ml µg/ml µg/ml µg/ml
0 0.91 0.19 2.4 <0.02 >50
24 >50 0.60 >50 0.18 >50
48 >50 0.22 >50 0.07 >50
72 >50 >50 >50 >50 >50
amAbs are shown as IC80 values.JEM VOL. 207, April 12, 2010 
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had no effect on CD4+ T cell infection by this R5 HIV-1 iso-
late. Rather, only subsets of PBMC that contained monocytes 
(purified monocytes, CD4+ T cell–depleted PBMC) could be 
protected from infection by the presence of anti-phospholipid 
mAbs (Table VI). Similar results were obtained using a Renilla 
luciferase reporter HIV-1 expressing the transmitted HIV-1 
env B.WITO (unpublished data). In separate experiments us-
ing HIV-1 primary isolates, mAbs PGN632 and CL1 inhib-
ited HIV-1 PVO in PBMC fractions containing monocytes 
but not in purified CD4+ T cells (Table S3). Thus, although 
anti-phospholipid mAbs could not directly inhibit CD4+ T 
cell infectivity with HIV-1, they could mediate abrogation of 
CD4+ T cell infection by HIV-1 in the presence of peripheral 
blood monocytes.
In addition, we determined if anti-phospholipid antibod-
ies could directly bind to lymphocytes and monocytes. Using 
flow cytometry to analyze cells treated in the same manner as 
in the PBMC assay, we found that mAbs PGN632 and CL1 
bound to a fraction of CD4+ T cells, whereas the other anti-
bodies tested showed no significant binding to CD4+ T cells 
(Fig. S4 A). Flow cytometry analysis of monocytes showed 
binding  of  all  antibodies  including  control  mAb  F39F,   
suggesting Fc receptor-mediated binding of the antibodies. 
Anti-phospholipid mAbs PGN632 and CL1 showed binding 
above the background, whereas small shifts were seen for IS4 
and P1 (Fig. S4 B).
Determination of the respective roles of the Fab and Fc 
components of anti-phospholipid antibodies in inhibiting 
HIV-1 infectivity of PBMC
To determine the role of the phospholipid-binding Fab portion 
of the anti-phospholipid mAbs in inhibiting HIV-1 infectiv-
ity, the PBMC assay was performed with mAbs preincubated 
with PBS, 2 mM cardiolipin, or 2 mM dioleoylphosphatidyl-
ethanolamine (DOPE; Fig. 1, E–H). When tested against 
B.6535, two of the antibodies, CL1 and PGN632, showed no 
change in potency when incubated with DOPE but did show 
a loss of potency after incubation with cardiolipin (reduction 
in IC80 of 11- and 200-fold, respectively). In contrast, IS4 
mAb showed little change upon incubation with either lipid. 
Thus, these data demonstrated a role of the antigen-specific Fab 
component of the antibody for mAbs P1, CL1, and PGN632 
as preincubation with lipids was able to block the inhibition of 
HIV-1 infection of PBMC.
To further evaluate the role of the Fab component of   
recombinant mAb IS4, variants of IS4 that had mutations of the 
heavy chain CDR3 arginines (which are required for phospho-
lipid binding) were studied (Giles et al., 2006). The panel of   
recombinant mAbs included IS4 expressed as IgG1 and paired 
with the native IS4 light chain, IS4 IgG1 heavy chain paired 
with a light chain from an anti-nucleosome mAb named B3 
(which differed solely in its pattern of somatic mutations from 
IS4VL; Mason et al., 2005) with enhanced cardiolipin and PS 
binding, and an engineered antibody with the native IS4 light 
chain paired with IS4 IgG1 containing two arginine-to-serine 
mutations at positions 96 and 97 in the CDR H3 loop that had 
Figure 1.  Anti-phospholipid mAbs inhibit infection by binding to 
host cells and inhibition can be blocked by lipids. (A–D) Antibodies 
were assayed by incubation with the challenge virus stock followed by 
introduction of the mixture to the target cells (red open points) or by incu-
bation with the PBMC targets and washing away of the excess before virus 
challenge (blue closed points). For each mAb, similar neutralization curves 
were seen. (A) PGN632 tested against SHIV SF162P3. (B) CL1 tested against 
B.QH0692. (C) IS4 tested against B.QH0692. (D) P1 tested against SHIV 
SF162P3. Data shown are representative of three experiments performed. 
(E–H) The PBMC infection assay was performed using HIV-1 B.6535 with 
mAb preincubated with PBS (black curve), 0.5 mM DOPE (blue curve), or  
0.5 mM cardiolipin (red curve). (E) PGN632. IC80 = 0.05 µg/ml after preincu-
bation with PBS; IC80 < 0.02 µg/ml after preincubation with DOPE; IC80 = 
10 µg/ml after preincubation with cardiolipin (200-fold reduction). (F) CL1. 
IC80 = 0.53 µg/ml after preincubation with PBS; IC80 = 0.53 µg/ml after 
preincubation with DOPE; IC80 = 5.8 µg/ml after preincubation with cardio-
lipin (11-fold reduction). (G) IS4. IC80 = 0.30 µg/ml after preincubation with 
PBS; IC80 = 0.18 µg/ml after preincubation with DOPE; IC80 = 0.33 µg/ml 
after preincubation with cardiolipin (no change). (H) P1. IC80 = 16 µg/ml after 
preincubation with PBS; IC80 = 26 µg/ml after preincubation with DOPE 
(1.6-fold reduction); IC80 = 7.2 µg/ml after preincubation with cardiolipin. 
Data shown are representative of three experiments performed.768 Anti-phospholipid antibody inhibition of HIV-1 | Moody et al.
been previously shown to abolish phospholipid binding (Giles 
et al., 2006). The two versions of the antibody that retained 
cardiolipin and PS binding both inhibited HIV-1 infection of 
PBMC with Renilla luciferase reporter HIV-1 expressing B.BaL 
env, whereas the recombinant mutated IS4 mAb that did not 
bind lipids did not inhibit HIV-1 infectivity (Table VII). Thus, 
collectively, these data demonstrated that the antigen-specific 
Fab regions of whole IS4, CL1, P1, and PGN632 mAbs are all 
required to mediate the anti–HIV-1 effect in vitro.
Next, a F(ab)2 fragment of the most potent mAb, PGN632, 
was produced and used to determine if the F(ab)2 bound 
to phospholipids with kinetics identical to the whole IgG 
PGN632 and to determine if the PGN632 F(ab)2 would also 
inhibit PBMC infection by HIV-1. Although intact PGN632 
and the F(ab)2 fragment had the same kon and koff when   
assayed for binding to cardiolipin, only the whole IgG1 
PGN632 was able to inhibit HIV-1 infection of PBMC 
(Fig. 2, A and B). Thus, both the Fab and Fc portions of in-
tact whole anti-phospholipid antibodies are required for inhi-
bition of HIV-1 infection of PBMC.
ADCVI activity of anti-phospholipid mAb
To determine if the anti–HIV-1 effect of anti-phospholipid 
antibodies was limited to the PBMC assay alone, mAb PGN632 
was tested for ADCVI. CEM.NKr.CCR5 target cells were   
infected with HIV-1 92US657 and mixed with PBMC effec-
tor cells at a 10:1 effector/target cell ratio. PGN632 IgG or 
PGN632 F(ab)2 was added, and 7 d later, virus output was 
measured. ADCVI activity was determined as the percentage 
of virus inhibition compared with a control mAb (Forthal   
et al., 2001). Similar to the results for the PBMC assay, whole 
IgG PGN632 at 50 µg/ml inhibited HIV-1 production by 
ADCVI (89.6 ± 4.3%), whereas PGN632 F(ab)2 produced 
no inhibition (20.6 ± 11.8%; Fig. 2 C).
Direct effects of anti-phospholipid antibodies on monocytes 
and CD4+ T cells in vitro
The requirement for the presence of monocytes in PBMC 
cultures for HIV-1 inhibition suggested that the anti-phospho-
lipid mAbs might have a direct effect on that cell type. 
Purified monocytes were cultured in the presence of anti-
phospholipid mAbs and control mAbs in vitro and assayed for 
evidence of a proliferative effect of the mAbs by incorporation 
of  3H-thymidine; however, none of the anti-phospholipid 
antibodies induced cell proliferation (Fig. S5 A). Similarly, CD4+ 
T cells cultured under similar conditions showed no evidence 
of proliferation by incorporation of 3H-thymidine (Fig. S5 A), 
nor did CD4+ T cells show evidence of increased apoptosis 
(Fig. S5, B–D). Although control anti–HIV-1 antibodies had 
little effect on monocyte morphology (Fig. S6 E), culture in 
the presence of anti-phospholipid mAbs for 4–7 d induced the 
formation of polykaryons (Fig. S6, A–D). In contrast, culture 
of monocytes in the presence of 10 µg/ml LPS did not in-
duce polykaryons (Fig. S6 F). Monocytes cultured with anti-
phospholipid mAbs were stained for markers of dendritic 
cells. The majority of polykaryons were monocyte-derived 
CD11c+, CD68+, and Langerin (Fig. S6, G, H, and J). 
There were rare Langerin+ polykaryons (Fig. S6 I), indicating 
that the anti-phospholipid mAbs induced the formation of 
polykaryons in dendritic cells as well. Culture of CD4+ T 
cells showed the development of blast forms (Fig. S6, K–S) 
but no evidence of polykaryons was seen.
Induction of PBMC CCR5 chemokines  
by anti-phospholipid antibodies
The combination of the specificity of anti-phospholipid mAbs 
for R5 HIV-1 isolates and the requirement for the presence 
of monocytes in the target cultures for HIV-1 inhibition sug-
gested that induction of R5 chemokines is important in the 
Table VII.  Effect of mutations of IS4 on inhibition of HIV-1 infection with NL-LucR.T2A-BaL.ecto in the PBMC assay
Heavy chain Light chain Binding to cardiolipin and PS (Giles et al., 2006) IC50 against B.BaL
µg/ml
IS4 IgG1 VH IS4 VL yes 10.4
IS4 IgG1 VH B3 VL yes 7.4
mutated IS4 IgG1 VHa IS4 VL no >50
aMutations in IS4 heavy chain are arginine-to-serine at positions 96 and 97.
Table VI.  Inhibition of HIV-1 infection with NL-LucR.T2A-BaL.ecto by mAbs in intact PBMC and PBMC cell subsets
mAb Target cell populationsa
Intact PBMC CD4+ T cells CD4+ T cell-depleted PBMC CD14+ monocytes CD14+ monocyte-depleted PBMC
µg/ml µg/ml µg/ml µg/ml µg/ml
PGN632 0.29 >50 0.31 0.18 >50
IgG1b12 6.2 4.6 0.57 0.65 5.1
2G12 0.39 4.6 0.06 0.03 5.0
4E10 40 41 47 32 42
aTarget cell populations are IC80 valuesJEM VOL. 207, April 12, 2010 
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mechanism of action of anti-phospholipid mAbs. All four 
anti-phospholipid mAbs were indeed potent inducers of, 
primarily, MIP-1 and MIP-1 and, to a lesser extent, 
RANTES from PBMC but not of the X4 chemokine SDF-1 
(Fig. 3 A). When neutralizing antibodies against the R5 che-
mokines were added to cultures of PBMC, the anti–MIP-1 
and anti–MIP-1 antibodies, but not the anti-RANTES 
antibody, blocked the ability of the anti-phospholipid mAb 
CL1 to inhibit HIV-1 infection (Fig. 3 B). Thus, the anti-
phospholipid antibodies that selectively inhibited the in vitro 
infectivity of R5 HIV-1 strains also triggered production of 
MIP-1 and MIP-1 anti–HIV-1 chemokines from periph-
eral blood monocytes. Prior experiments demonstrated that 
other mAbs directed against HIV-1 (F39F and 17b), as well 
as the non–HIV-1 mAb Synagis, did not stimulate the pro-
duction of chemokines (Fig. S7 A). To determine if the mAbs 
could have this effect on CD4+ T cells alone, we cultured 
purified CD4+ T cells in the presence of the anti-phospholipid 
antibodies and control mAbs and found that none of the 
antibodies directly stimulated the production of chemokines 
from CD4+ T cells (Fig. S7 B).
Endotoxin stimulation of monocytes does not account  
for the activity of anti-phospholipid antibodies  
in the PBMC assay
As noted in Materials and methods, all antibody stocks were 
tested for the presence of endotoxin and were found to either 
have no detectable endotoxin or to have no more than 1 pg of 
endotoxin per 1 mg/ml of antibody stock. To directly test the 
effect of endotoxin in the PBMC assay, the PBMC assay was 
performed in the presence of LPS. At least 4 µg/ml of endo-
toxin was required for 80% inhibition of HIV-1 infection, an 
amount that far exceeded the amount of endotoxin detected in 
mAb preparations (unpublished data). These data, in concert 
with those demonstrating the requirement of both the Fab and 
Fc components of IgG anti-phospholipid mAbs for HIV-1 in-
hibition, demonstrated that endotoxin contamination was not 
responsible for the observed anti–HIV-1 activity.
Culture supernatants from anti-phospholipid antibody-
stimulated PBMC inhibit HIV-1 pseudovirus infection  
of TZM-bl cells
The lack of monocytes in the TZM-bl pseudovirus neutral-
ization assay could explain the absence of activity of the anti-
phospholipid antibodies in that assay. Therefore, supernatants 
from PBMC that had been incubated with anti-phospholipid 
antibodies were transferred into TZM-bl cell cultures to 
determine if chemokine secretion by monocytes could block 
pseudovirus infection. As before, anti-phospholipid antibodies 
alone did not neutralize, nor did supernatants from cells not 
Figure 2.  Intact whole-molecule PGN632 inhibits HIV-1 infection 
but Fab and F(ab)2 fragments do not. (A) SPR characterization of the 
cardiolipin binding of intact PGN632, PGN632 Fab, and PGN632 F(ab)2. 
The intact mAb and the bivalent F(ab)2 have similar kinetics of binding to 
cardiolipin. In contrast, the monovalent Fab has a greater than fivefold 
faster koff, indicating the loss of avidity compared with the intact mAb.  
(B) PBMC assay of PGN632 and fractions. Intact PGN632 inhibited the 
infection of both NL-LucR.T2A.BaL.ecto and NL-LucR.T2A.WITO.ecto in the 
PBMC assay (IC80 = 0.06 and 0.03 µg/ml, respectively), as did mAb 4E10 
with a less potent IC80 (5.0 and 4.7 µg/ml, respectively). In contrast, both 
the bivalent F(ab)2 and the monovalent Fab failed to inhibit, as did the 
control anti-RSV mAb. Data shown are representative of three experi-
ments performed. (C) ADCVI assay was performed using HIV-1 92US657 
as described in Materials and methods. Data shown are representative of 
three experiments performed. Final antibody concentrations are as shown. 
Data are normalized to a control mAb. The human antibody preparation 
HIVIG was used as a positive control. At the highest concentration (50 µg/ml), 
HIVIG produced 97.2% inhibition and whole intact PGN632 mAb pro-
duced 87.9% inhibition, whereas PGN632 F(ab)2 produced no inhibition 
(11.4%). These data demonstrate the requirement for intact mAb con-
taining Fc to mediate inhibition of HIV-1 infection.
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incubated with anti-phospholipid antibodies. However, super-
natants from PBMC incubated with anti-phospholipid anti-
bodies were able to block pseudovirus infection of TZM-bl 
cells (Fig. 3 C). Thus, transfer of supernatants produced by 
anti-phospholipid antibody-treated PBMC recapitulated in the 
TZM-bl assay the HIV-1 inhibitory activity of anti-phospho-
lipid antibodies seen in the PBMC assay.
DISCUSSION
In this paper, we define a mechanism of inhibition of HIV-1 
infection of human PBMCs by human anti-phospholipid 
antibodies. Anti-phospholipid mAbs derived from human sub-
jects can be classified into two types: those that are dependent 
on the presence of 2GP1 for binding and those that are not 
(Zhu et al., 1999; Iverson et al., 2002; Ioannou et al., 2007; 
Lin et al., 2007). Although not an absolute correlation, those 
mAbs that require 2GP1 for binding to phospholipids have 
been associated with autoimmune phenomena, including 
an increase in thrombogenesis and with adverse clinical out-
comes (Alving, 2006; Lin et al., 2007), whereas those mAbs 
that bind directly to phospholipids and that do not require 
2GP1 for binding are not (Iverson et al., 2002; Ioannou et al., 
2006). In addition, naturally occurring antibodies against phos-
pholipids can be found in healthy individuals and are not 
associated with negative clinical consequences (Alving, 2006). 
Thus, antibodies that bind to phospholipids are not always 
pathological, and those that possess additional beneficial 
properties, such as virus inhibition (Brown et al., 2007; Soares 
et al., 2008) or antitumor effects (Ran et al., 2005), could be 
of  interest  as  candidates  for  therapeutic  monoclonal  anti-
bodies or for induction by vaccines.
The mAbs studied in this paper were generated from   
peripheral blood antibody libraries of healthy subjects or from 
blood B cells of primary and secondary anti-phospholipid   
antibody syndrome (APS) subjects. HIV-1–inhibiting anti-
phospholipid antibodies were effective up to 48 h after HIV-1 
contact with PBMC, broadly neutralized only R5 but not X4 
HIV-1, and acted on peripheral blood monocytes to induce 
R5 chemokines. Collectively, these data explain why anti-
phospholipid antibodies inhibit HIV-1 infectivity in PBMC 
but not in CD4+ CCR5+ transfected epithelial cell assays such 
as the TZM-bl assay (Montefiori, 2005), and they demon-
strate a novel mechanism whereby components of the adap-
tive immune system can activate antiviral innate immunity.
The  target  of  the  anti-phospholipid  antibodies  in  the 
PBMC HIV-1 infection assay was not HIV-1 virions. Of the 
four mAbs that inhibited HIV-1 infectivity in PBMCs, only 
one, PGN632, weakly bound HIV-1 virions in SPR with a 
fast off rate (Fig. S3, B–D). These mAbs induced chemokines 
and cytokines to the point of inducing monocyte polykaryon 
Figure 3.  Chemokines mediate the anti–HIV-1 activity of anti-
phospholipid antibodies. (A) Monocytes were cultured in the presence or 
absence of antibodies, and culture supernatants at 24 h were assayed for 
the presence of chemokines. The four anti-phospholipid mAbs PGN632, 
CL1, IS4, and P1 potently induced MIP-1 and MIP-1, along with lower 
levels of RANTES. The anti–HIV-1 mAb A32 did not induce any chemokine 
production. None of the antibodies induced SDF-1. Data shown are means 
of three wells per point, error bars are SEM, and all are representative of 
three experiments performed. (B) The activity of CL1 against HIV-1 B.6535 
in PBMC was tested in the presence of anti-chemokine blocking antibod-
ies. Productive infection was observed in the absence of any antibody, and 
that infection was inhibited by the presence of CL1 mAb. Control blocking 
antibody P3X63/Ag8 did not alter the ability of CL1 to inhibit HIV-1 infec-
tion, nor did a blocking anti-RANTES antibody. In contrast, blocking anti-
bodies against MIP-1 and MIP-1 restored infection, abrogating the 
inhibitory effect of CL1 mAb. Data shown are representative of three ex-
periments performed. (C) The activity of PGN632 and CL1 mAbs were 
tested in the standard PBMC infectivity assay against NL-LucR.T2A.WITO.
ecto (IC80 = 0.08 and 0.80 µg/ml, respectively) and in the TZM-bl pseudo-
virus neutralization assay using a pseudovirus construct expressing the 
same env (IC80 >50 for both). Additionally, PBMCs were triggered by incu-
bation with mAb for 24 h and cell-free supernatants transferred to TZM-
bl cultures followed by addition of pseudovirus. Supernatants triggered 
with control antibodies did not inhibit (not depicted), whereas those trig-
gered with PGN632 and CL1 inhibited with IC80 = 0.09 and 5.1 µg/ml, 
respectively, demonstrating that soluble factors produced in the PBMC 
cultures mediated inhibition of HIV-1 infectivity. Data shown are repre-
sentative of three experiments performed.
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formation in vitro (Fig. S6, A–F). R5 but not X4 chemo-
kines were induced, with the production of MIP-1 and 
MIP-1 exceeding that of RANTES (Fig. 3 A), and antisera 
against MIP-1 and MIP-1 abrogated the ability of lipid 
antibodies to inhibit HIV-1 infectivity of PBMC (Fig. 3 B). 
Thus, virus inhibition by the anti-phospholipid antibodies is 
not the result of viral neutralization but rather occurs through 
in vitro modulation of PBMC by adaptive antibodies, resulting 
in inhibition of HIV-1 infectivity.
Three of the antibodies (PGN632, P1, and CL1) that in-
hibit HIV-1 infection bind directly to phospholipids, whereas 
one (IS4) requires 2GP1 for binding. The importance of 
the Fab region in binding is shown by the ability of the an-
ionic phospholipid cardiolipin to block the HIV-1 inhibition   
activity of CL1 and PGN632 mAbs (Fig. 1, E–H). For IS4, 
the requirement for Fab binding was shown by use of the re-
combinant IS4 variants with those variants that retain lipid 
binding showing activity in the PBMC assay. These data are 
consistent  with  direct  signaling  for  chemokine  induction 
through lipids or lipid-dependent signaling complexes. PS   
is a tenable target, as it is recognized by all four HIV-1 inhib-
itory mAbs, appears to be present constitutively on macro-
phage lineage cells (unpublished data), and is up-regulated on 
activated (Bevers et al., 1983) and virally infected cells (Soares 
et al., 2008). PS is enriched in lipid rafts, membrane micro-
domains which are known to be associated with cell signaling 
events. Although cardiolipin is also recognized by the four 
mAbs, cardiolipin is itself unlikely to be a target as it is pre-
dominantly a component of mitochondrial lipid membranes 
(Schlame and Hostetler, 1997). The differing potencies of the 
four mAbs also suggested that the particular lipid motif bound 
by PGN632 and CL1 antibody Fab regions may be similar 
but that mAbs P1 and IS4 Fab region lipid binding motifs 
may differ. Thus, it is possible that the activity of certain anti-
bodies involves binding to an unidentified lipid target in 
addition to PS.
Although the Fab regions of the four anti-phospholipid 
antibodies were clearly required for HIV-1 inhibition activity, 
the Fc region was also clearly required. The F(ab)2 of mAb 
PGN632, the most potent anti-phospholipid mAb, did not 
inhibit HIV-1 infectivity in the PBMC assay and did not sup-
port ADCVI (Fig. 2, B and C, respectively). This finding was 
not a result of altered binding of the F(ab)2 to lipids, as the 
F(ab)2 koff for binding to lipids was identical to that of the 
whole IgG by SPR (Fig. 2 A). Thus, both the Fab and the Fc 
regions of the anti-phospholipid antibodies, together as an 
intact molecule, were required for mediating the HIV-1 in-
hibition effect of the anti-phospholipid antibodies. Trigger-
ing via the Fc receptor of IgG has been reported to stimulate 
chemokine release from natural killer cells (Forthal et al., 
2001, 2005), monocytes (Fernández et al., 2002), and den-
dritic cells (Radstake et al., 2005), and these data raise the 
possibility of synergy between two modes of triggering (e.g., 
lipid binding and FcR ligation; polyspecific triggering by anti-
body Fab plus FcR binding). Although the data in Table VI 
and Table S3 suggest that monocytes alone can mediate these 
effects, the role of other cells, such as NK cells, has not been 
rigorously excluded. It was notable that the inhibitory effect 
of anti-phospholipid antibodies was seen in only 85% of the 
PBMC tested. The lack of activity in PBMC that did not 
support the phenomenon could be the result of an inability   
to produce the correct chemokines, alteration in a cellular   
receptor, or differences in signaling pathways. Thus, it will be 
important to determine the mechanism of induction of che-
mokines and cytokines by anti-phospholipid antibodies and 
to determine the roles of each of the cell surface targets of this 
activity on multiple FcR+ cell types.
It was of considerable interest that anti-phospholipid anti-
bodies did not induce X4 chemokines but only R5 chemo-
kines. In vitro protective effects of R5 chemokines secreted 
by neonatal natural killer cells have been previously described 
(Bernstein et al., 2004), and antigen-specific production of 
R5 chemokines in vitro has been reported to correlate with 
decreased  viral  loads  in  HIV-1–infected  subjects  (Ferbas   
et al., 2000). Kinter et al. (1998) reported that R5 virus inhi-
bition through the use of -chemokines can be correlated 
with the enhancement of X4 isolate replication. This effect 
was most pronounced for RANTES and less substantial for 
MIP-1. In contrast, in our study RANTES was minimally 
induced, whereas MIP-1 was increased to the greatest extent 
(Fig. 3 A) and the use of anti-RANTES antibodies showed 
little effect on the antiviral activity of mAb CL1 (Fig. 3 B). In 
addition, Keele et al. (2008) have recently shown that the 
transmitted/founder virus almost always utilizes CCR5 and 
not CXCR4. The anti-phospholipid antibodies studied were 
as potent at inhibiting the infectivity of R5 but not X4 trans-
mitted/founder viruses as they were against chronic HIV-1 
strains (Tables III and IV). It will be of interest to dissect the 
triggering mechanisms of CCR5 versus CXCR4 inhibition 
chemokines to understand how to differentially trigger both 
types of anti–HIV-1 innate molecules. Before the use of an 
intervention based on the findings of this study in human sub-
jects, it will also be important to determine the potential for 
a shift from R5 to X4 infection in the presence of anti-
phospholipid antibody-mediated anti–HIV-1 activity.
That  the  anti-phospholipid  mAbs  induced  monocyte 
polykaryon formation in vitro was an indication of the stimu-
latory capacity of the mAbs for peripheral blood monocytes. 
In addition to induction of R5 chemokines, lower levels of 
TNF, IL-6, IL-4, and IFN- are induced in vitro. IFN- and 
IL-4 have been reported to induce polykaryon formation 
(McNally and Anderson, 1995), and it is likely that these   
cytokines may be the mediators of this in vitro phenomenon. 
The observation of Langerin+ polykaryons in these cultures 
suggested that lipid antibodies may also act on dendritic cells 
as well as peripheral blood monocytes in culture (Fig. S6 I), 
although we have not studied this exhaustively.
There are prior studies of antibodies from autoimmune 
disease patients that have shown cross-reactivity with HIV-1 
antigens (Douvas and Takehana, 1994; Scherl et al., 2006) 
and even descriptions of in vitro neutralization by such anti-
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showing the requirement of the mAbs for the presence of 2GP1 for lipid 
binding are in Fig. S1 (A and B) or have been previously reported (Lin et al., 
2007). MAbs 7B2, F39F, 17b, and A32 were gifts of J. Robinson (Tulane 
University, New Orleans, LA). Goat anti–human IgG (H+L) was purchased 
from KPL, Inc. All mAbs were used at saturating concentrations.
Flow cytometry. Flow cytometry staining was performed as described pre-
viously (Levesque et al., 2009). Antibodies were titered to optimal concen-
trations before use. For staining of PBMC using anti-phospholipid mAbs, 
the antibodies were labeled using a Zenon anti–human Alexa Fluor 488 kit 
(Invitrogen) according to the manufacturer’s instructions. Staining of CD4+ 
T cells was performed using two-step immunofluorescence with an FITC-
labeled  goat  anti–human  IgG  (H+L)  reagent  (Jackson  ImmunoResearch 
Laboratories). Samples were acquired using an LSR II (BD) and analyzed   
using FlowJo software (Tree Star, Inc.).
Recombinant Envs and other reagents. RPMI-1640, PBS, PBS with 
1% BSA, and gentamicin were purchased from Invitrogen. Methanol-free 
formaldehyde  10%  was  purchased  from  Polysciences,  Inc.  Recombinant 
gp140CF or gp140CFI group M consensus CON-S, JRFL Env oligomers 
were produced in recombinant vaccinia viruses as secreted proteins as previ-
ously described (Liao et al., 2006). LPS was purchased from Sigma-Aldrich.
Lipid binding by ELISA. Binding of mAbs to aminophospholipids such as 
PS and cardiolipin was evaluated by ELISA. Lipids were dissolved in hexane 
at 5 µg/ml, and 100 µl was added to coat wells of 96-well plates. The hexane 
solution was allowed to evaporate, leaving lipids bound to the plates. Plates 
were then blocked for 2 h at 37°C with either 2% (wt/vol) bovine serum   
albumin (lacking 2GP1) in PBS or 10% (vol/vol) fetal bovine serum in PBS 
to provide a source of 2GP1. Parallel experiments were performed using 
recombinant 2GP1 in place of fetal bovine serum. The plates were washed 
three times with PBS. Antibodies (Table I) made in the same diluent used in 
blocking of the plates were added to the wells and incubated (2 h at 37°C). 
The plates were washed three times with PBS. Binding mAbs to the immo-
bilized lipids were detected using a goat anti–human IgG (H&L) conjugated 
to horseradish peroxidase (incubated 45 min at 37°C). The plates were 
washed three times with PBS. Tetramethyl benzidine substrate was added for 
color development, followed by 2 M H2SO4 to stop the substrate reaction, 
and the plates were read at 450 nm.
Isolation of human PBMC, CD4+ T cells, and monocytes. Peripheral 
blood and leukophereses were obtained from healthy donors under clinical 
protocols approved by the Duke University Institutional Review Board. 
Additional PBMCs were obtained as discarded buffy coats from the Ameri-
can Red Cross. PBMCs were isolated using Hypaque-Ficoll density gradi-
ents by standard techniques. Cells were negatively selected for peripheral 
blood CD4+ T cells or monocytes using an autoMACS Pro Separator 
(Miltenyi Biotec). Monocytes were also isolated by elutriation of leuko-
pheresis product and repurification using the autoMACS system if needed. 
Resulting cell preparations were analyzed by staining with CD14, CD20, 
CD3, CD4, and CD8 antibodies and analyzed on either an LSR II or a 
Guava EasyCyte Mini-SSC system (Millipore). All CD4+ T cell preparations 
were ≥95% CD3+CD4+ and monocyte preparations were ≥95% CD14+.
SPR. Binding of mAbs to lipids, virions, and HIV-1 Env proteins was studied 
using SPR. SPR studies were performed using standard techniques on a Biacore 
3000 (GE Healthcare) as previously described (Alam et al., 2007, 2008).
Virus capture assay. Virus capture assays were performed by a modification 
of a published method (Poignard et al., 2003). In brief, 96-well ELISA plates 
were coated overnight at 4°C with mAbs at 5 µg/ml in 0.1 M sodium bicar-
bonate, pH 9.6. The plates were washed twice with PBS containing 0.1% 
Tween-20 and blocked for 1 h at room temperature with 150 µl/well PBS 
containing 4% whey protein. The plates were washed twice with PBS con-
taining 0.1% Tween-20 and once with plain PBS. Pseudovirus B.BG1168 or 
with HIV-1 Env proteins and have not been targeted at host 
cell or virion lipids. Thus, the antibodies described in this   
paper represent a novel group of polyspecific antibodies wor-
thy of further investigation to determine their potential role 
in protecting subjects with these antibodies from R5 HIV-1 
infection. The ability of such antibodies to stimulate similar 
effects in vivo has yet to be determined. In separate studies, 
plasma was obtained from patients with autoimmune diseases 
and tested for anti-phospholipid antibody activity and for   
the presence of -chemokines with no observed correlation 
between their levels (unpublished data). In another study, pa-
tients infected with HIV-1 and coinfected with syphilis were 
studied, and it was found that the presence of RPR-positive 
syphilis, and therefore the presence of anti-cardiolipin anti-
bodies, was associated with greater HIV-1 inhibition in the 
PBMC assay compared with HIV-1–negative patients with 
syphilis infection and compared with HIV-1 patients without 
syphilis (unpublished data). Whether this anti–HIV-1 activity 
is a result of the same mechanism as that of the mAbs in this 
study has yet to be determined.
The development of new therapies for the prevention of 
HIV-1 has suffered major setbacks in efficacy trials of vaccines 
(Sekaly, 2008) and microbicides (van de Wijgert and Shattock, 
2007). In HIV-1 vaccine development, recent studies have 
demonstrated the extremely early destruction of the immune 
system and early induction of immunosuppression and apop-
tosis (Gasper-Smith et al., 2008; Tomaras et al., 2008; Levesque 
et al., 2009; Stacey et al., 2009), signaling the need for a vac-
cine that can prime for a very early salutary immune response 
within days of infection. The novel mechanism outlined in 
this paper of anti-phospholipid antibody modulation of anti–
HIV-1 chemokines accounts for the selective activity of lipid 
antibodies in PBMC but not epithelial-based cultures. These 
results suggest that a vaccine could potentially harness the adap-
tive immune system to trigger innate immunity for an antiviral 
response, in effect reversing the traditional path of protection 
of innate to adaptive immunity.
MATERIALS AND METHODS
Antibodies. MAbs used in this study and their characteristics are shown in 
Table I. IS4, B1, and B2 are human mAbs originally derived from patients 
with primary APS (Zhu et al., 1999; Lin et al., 2007). Recombinant native 
IS4 and variant forms were produced as described previously (Giles et al., 
2006). CL1 and P1 are human mAbs derived from patients with systemic   
lupus erythematosus (SLE) and secondary APS (Zhu et al., 1999; Lin et al., 
2007), and PGN632, PGN634, and PGN635 are recombinant mAbs derived 
from a peripheral blood antibody library from a normal subject. PGN632 was 
engineered to optimize binding to phosphatidylserine (PS). The cardiolipin 
binding motifs present in the CDR H3 sequences of IS4, CL1, PGN632, 
PGN634, and PGN635 are shown in Table S4. Except for the panel of re-
combinant IS4 mAbs, each cell line was grown in serum-free media and 
whole immunoglobulin purified using protein A/G preparative columns. 
The control antibody Synagis (palivizumab) is a humanized mAb against the 
F-protein of respiratory syncytial virus (MedImmune). Anti-gp41 membrane 
proximal external region mAbs 2F5 and 4E10 were purchased from Polymun 
Scientific Immunbiologische Forschung GmbH. All antibodies used for HIV-1 
inhibition assays were tested for the presence of endotoxin using a limulus 
amoebocyte lysate assay and were found to either have no detectable levels of 
endotoxin or to have <1 pg endotoxin per 1 mg/ml of antibody stock. Data JEM VOL. 207, April 12, 2010 
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control infected wells and expressed as mAb IC80 in micrograms per milli-
liters. Assay stocks of virus were grown and titrated in PBMC.
Studies of mAbs preabsorbed with lipids were performed with antibody 
stocks incubated with 2 mM cardiolipin, 2 mM DOPE, or PBS at 37°C for 
2 h or overnight, after which the mixture was assayed as described in the 
previous paragraph. Time course studies were performed by adding mAb at 
0, 24, 48, or 72 h. In these experiments, antibody was reintroduced after 
each wash step so that a constant concentration of antibody was present 
throughout the assay.
ADCVI assays. ADCVI antibody activity was measured essentially as de-
scribed previously (Forthal et al., 2001; Hessell et al., 2007). In brief, target 
cells were prepared by infecting CEM.NKr.CCR5 cells (National Institutes 
of Health AIDS Research and Reference Reagent Program) with the R5 
HIV-1 clinical isolate 92US657 at an MOI of 0.05 for 24 h. The target cells 
were washed and incubated with mAbs at indicated final concentrations and 
with fresh PBMC effector cells from normal healthy donors (effector/target 
ratio of 10:1). After 7 d, supernatant fluid from duplicate wells was assayed 
for p24 by ELISA (ZeptoMetrix Corporation). Percentage of virus inhibi-
tion was calculated by referencing the p24 from controls wells containing 
effector cells and isotype-matched mAb at corresponding concentrations.
Induction of polykaryon formation in peripheral blood monocytes 
and of lymphoblast formation in CD4+ T cells. Human peripheral 
blood  monocytes  (≥95%  CD14+)  or  CD4+  T  cells  (≥95%  CD4+)  were 
brought to a final concentration of 106 cells/ml and placed into 6-well plates 
or 8-chamber slides and grown at 37°C in 5% CO2 in IL-2 growth media 
containing 10 µg/ml of antibody or 10 µg/ml of LPS at final concentration. 
Cells were examined during culture using inverted phase-contrast micros-
copy. At 4–7 d after the start of culture, chamber slides were cleared of me-
dia and Wright-giemsa stained for visual microscopy. Cultures in 6-well 
plates were harvested by pipetting and cell scraping and cells deposited on 
slides using Cytospin funnels (Thermo Fisher Scientific) before Wright-
giemsa staining or indirect immunohistochemistry. For immunohistochem-
istry, slides were treated when required for antigen retrieval using standard 
techniques (Maeda et al., 2002) and stained with saturating amounts of the 
monoclonal or polyclonal antibodies against Langerin, CD11c (Leica), and 
CD68 (Dako). Secondary stains were with horseradish peroxidase–labeled 
polyclonal IgG (H+L) against the species of the primary antibody followed 
by development with 3,3-diaminobenzidine in the presence of hydrogen 
peroxide. Photomicrographs were acquired on a microscope (Vanox AH-3; 
Olympus) outfitted with a digital camera (D-70; Olympus) and using DP 
Controller & Manager software (Olympus). Images were acquired at a 60× 
magnification (Fig. S6, A–F and K–R) using a Dplan Apo 60–0.90 NA ob-
jective lens (Olympus) or at a 100× magnification (Fig. S6, G–J) using an 
SPlan 100–1.25 NA oil lens (Olympus). Images were not manipulated after 
acquisition other than by cropping and the addition of 10-µm scale bars.
Cellular  proliferation  by  3H-thymidine  incorporation  and  cell 
counts. Intact PBMC, purified monocytes, and purified CD4+ T cells were 
incubated in the presence of polyclonal stimulation (PHA or pokeweed mi-
togen) or in the presence of varying concentrations of mAbs as indicated 
(Fig. S5 A). Cellular proliferation was determined by the incorporation of 
3H-thymidine as previously described (Haynes and Fauci, 1978). In parallel 
experiments, CD4+ T cells were incubated in the presence of 10 µg/ml of 
mAbs and were assayed by cell counting and viability measurement using an 
EasyCyte cell counter (Millipore).
Multiplex chemokine assays. Plasma samples and culture supernatants 
were analyzed for soluble levels of MIP-1, MIP-1, Eotaxin, RANTES, 
MCP-1, and SDF-1 on the Bio-Plex Xmap system (Bio-Rad Laboratories) 
using luminex bead-based assays. MIP-1, MIP-1, Eotaxin, RANTES, 
and MCP-1 levels (in picograms per milliliter) were determined with a com-
mercially available kit (Invitrogen) as a custom five-plex assay as per the 
manufacturer’s instructions. SDF-1 levels (in picograms per milliliter) were 
B.SF162LS (100 µl at 2–5 × 105 TCID50/ml) was added to the wells alone 
or after preincubation for 1 h with soluble CD4 at 50 µg/ml. The wells were 
washed three times with PBS and then harvested using 100 µl/well PBS 
containing 0.5% Triton X-100. Captured virus was measured using p24 
ELISA (Abbott Laboratories).
Neutralization assay in TZM-bl cells. Neutralizing antibody assays in 
TZM-bl cells were performed as described previously (Montefiori, 2005). 
Antibodies were tested starting at a 50 µg/ml final concentration and titered 
using serial threefold dilutions. Pseudoviruses were added to the antibody 
dilutions at a predetermined titer to produce measurable infection and   
incubated for 1 h. TZM-bl cells were added and incubated for 48 h before 
lysis, after which supernatant was measured for firefly luciferase activity by a 
luminometer. The data were calculated as a reduction in luminescence com-
pared with control wells and reported as mAb IC50 in µg/ml (Montefiori, 
2005). For some experiments, PBMCs or purified monocytes were stimu-
lated by antibodies as described in Neutralization assay in PBMCs, and the 
conditioned culture supernatants were harvested and then added to TZM-bl 
cell cultures for detection of the inhibitory activity of triggered supernatants. 
All Env-pseudotyped viruses were prepared in 293T cells and titrated in 
TZM-bl cells as previously described (Montefiori, 2005).
Antibody inhibition of HIV-1 induced syncytium formation. Syn-
cytium inhibition assays were performed using 2,2-dipyridyl disulfide 
  (Aldrithiol-2) inactivated virions (gift from L. Arthur and J. Lifson, Frederick 
Research Cancer Facility, Frederick, MD). Antibody prepared in serial dilu-
tion was incubated with inactivated virions for 1 h at 37°C. SUP-T1 cells, 
grown in 10% FBS in RPMI 1640 with 50 µg/ml gentamicin, were added to 
the antibody-virus mixture and incubated for 16 h at 37°C in 5% CO2. Syncytia 
were imaged using inverted phase-contrast microscopy and counted. Titers 
were expressed as the concentration of antibody that inhibited 90% of syncy-
tium formation compared with wells containing no antibody.
Neutralization assay in PBMCs. PBMC infectivity inhibition assays were 
performed using primary HIV-1 isolates or SHIV viruses to infect PBMC 
with infection detected using p24 ELISA as previously described (Pilgrim   
et al., 1997). In brief, cryopreserved human PBMCs were thawed and acti-
vated in culture for 1 d in IL-2 growth medium (RPMI 1640 with 2 mM   
L-glutamine, 25 mM Hepes, 20% heat-inactivated fetal bovine serum, 5% 
IL-2, and 50 µg/ml gentamicin) containing PHA-P at 5 µg/ml. Cells were 
then washed and added to U-bottom wells containing antibody or serum   
dilutions as appropriate and incubated for 1 h before adding HIV or SHIV 
isolates at an appropriate dilution. After 24 h, the cells were washed four times 
with IL-2 growth medium and then incubated for a further 24–96 h. 25 µl of 
media was removed and incubated with 225 µl 0.5% Triton X-100 and then 
assayed by p24 ELISA. Data were calculated as a reduction of p24 production 
compared with control infected wells and expressed as mAb IC80 in micro-
grams per milliliter. Assay stocks of virus were grown and titrated in PBMC.
In some experiments, PBMC assays were conducted with replication-
competent Renilla luciferase reporter viruses engineered to express transmit-
ted and chronic env gene sequences of choice in cis in an isogenic backbone 
in which all other viral proteins are expressed and in which the reporter gene 
is genetically stable. The construction and utility of these reagents have been 
described elsewhere (Ochsenbauer and Kappes, 2009). In brief, the reporter 
viruses included in this study (collectively named NL-LucR.T2A-ENV.ecto 
in which ENV is replaced by the designation of the inserted env sequences, 
respectively) express the respective ectodomains (i.e., all of gp120 and the 
ectodomain and membrane-spanning domain of gp41) of the Env proteins 
listed in Table IV. The cytoplasmic domain of gp41 is derived from NL4-3, 
thereby avoiding chimerisms in tat, rev, and vpu. PBMCs were infected essen-
tially as described in the previous paragraph with viruses produced in PBMC; 
however, input virus was not washed out after 24 h, and cells were lysed 4 d 
after infection. The level of infection in each sample was determined by mea-
suring virally encoded Renilla luciferase activity in cell lysates on a luminome-
ter. Data were calculated as a reduction of relative light units compared with 774 Anti-phospholipid antibody inhibition of HIV-1 | Moody et al.
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